Potential of molecular targeted therapy of HER-2 and COX-2 for invasive transitional cell carcinoma of the urinary bladder

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1577-1583

  Naruse, Katsuya ^a   Yamada, Yoshiaki ^a   Nakamura, Kogenta ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Zennami, Kenji ^a   Katsuda, Remi ^a   Watanabe, Masahito ^a   Nishikawa, Genya ^a   Itoh, Youko ^a   Mitsui, Kenji ^c   Hibi, Hatsuki ^b   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kyouritsu General Hospital   (Japan)

^c Tokoname Municipal Hospital   (Japan)

Author keywords

Cyclooxygenase 2; HER 2; Immunohistochemistry; Invasive bladder carcinoma; Molecular targeted therapy

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOLECULAR THERAPY; OUTCOME ASSESSMENT; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; UNIVERSITY HOSPITAL; CARCINOMA, TRANSITIONAL CELL; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77951733042     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000798     Document Type: Article

References (30)

1. Schuster TG, Smith DC and Montie JE: Pelvic recurrences post-cystectomy: current treatment strategies. Semin Urol Oncol 19: 45-50, 2001.
2. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
3. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
4. Von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
5. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J and Kumar R: Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18: 305-314, 1999.
6. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22: 1435-1448, 1998.
7. Sobin LH and Wittekind Ch (eds). TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, pp199-202, 2002.
8. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
9. Matsubara H, Yamada Y, Naruse K, et al: Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep 19: 57-63, 2008.
10. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
12. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
13. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
14. Dybdal N, Leiberman G, Anderson S, et al: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93: 3-11, 2005.
15. De Pinieux G, Colin D, Vincent-Salomon A, Couturier J, Amsellem-Ouazana D, Beuzeboc P and Vieillefond A: Confrontation of immunohistochemistry and fluorescence in situ hybridization for the assessment of HER-2/neu (c-erbB-2) status in urothelial carcinoma. Virchows Arch 444: 415-419, 2004.
16. Caner V, Turk NS, Duzcan F, et al: No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 14: 261-266, 2008.
17. Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A and Syrjanen K: Use of immunohistochemically demonstrated c-erbB-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 20: 238-242, 1991.
18. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95: 1009-1015, 2002.
19. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN and Kumar R: Prognostic significance of HER2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40: 321-327, 2008.
20. Kruger S, Weitsch G, Buttner H, et al: Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21: 981-987, 2002.
21. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257, 1999.
22. Grubbs CJ, Lubet RA, Koki AT, et al: Celecoxib inhibits N-butyl- N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60: 5599-5602, 2000.
23. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369, 2000.
24. Shirahama T: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6: 2424-2430, 2000.
25. Yu DS, Chen HI and Chang SY: The expression of cyclooxygenase in transitional cell carcinoma cell lines: its correlation with tumor differentiation, invasiveness and prostanoids production. Eur Urol 44: 491-494, 2003.
26. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM and Lerner SP: Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169: 938-942, 2003.
27. Shirahama T, Arima J, Akiba S and Sakakura C: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92: 188-193, 2001.
28. Kim SI, Kwon SM, Kim YS and Hong SJ: Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60: 816-821, 2002.
29. Dovedi SJ, Kirby JA, Davies BR, Leung H and Kelly JD: Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 54: 621-630, 2008.
30. Eltze E, Wulfing C, von Struensee D, Piechota H, Buerger H and Hertle L: Cox-2 and HER2/neu co-expression in invasive bladder cancer. Int J Oncol 26: 1525-1531, 2005.